ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 427

Identifying Barriers to Zoster Vaccination Rates Among RA Patients in an Academic Rheumatology Practice

Ami Joglekar1, Ashley Blaske2 and Narender Annapureddy3, 1Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, 2Internal Medicine/Pediatrics, Vanderbilt University, Nashville, TN, 3Vanderbilt University, Nashville, TN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: quality improvement, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The risk of herpes zoster (HZ) infection in patients with rheumatic disease is 1.5 to 2 times that of the general population. The 2012 ACR Treatment Guidelines for rheumatoid arthritis (RA) added HZ vaccination as a recommendation in accordance with CDC guidelines. Studies have shown HZ vaccination rates among RA patients ranging 1%–21%. We assessed HZ vaccination rates based on documentation in an academic practice with a focus on location of primary care provider (PCP).

Methods: A retrospective chart review of 639 RA patients (one-time ICD 9 code 714.0) seen by physician rheumatology providers from December 1, 2014 to June 30, 2015 was conducted. 50% of all eligible patients per provider were randomly selected for chart review. Patients with RA age ≥ 60 were included. Exclusion criteria were: 1. age < 60 2. biologic therapy 3. prednisone ≥ 20 mg/day for ≥ 14 days; MTX > 0.4 mg/kg/wk; azathioprine > 3 mg/kg/day 4. ongoing chemotherapy or radiation OR cancer remission < 3 mos 5. immunodeficiency 6. solid organ transplantation 7. HIV patients with CD 4 count < 200 8. pregnancy. An additional 61 patients were excluded for the following reasons: wrong diagnosis, seen outside the time frame, or not seen in rheumatology clinic. The primary outcome was vaccination status and difference in vaccination rates based on location of PCP. Chi-square was used to compare categorical variables.

Results: 193 patients met inclusion criteria. 89.2% were white and 77.3% female with a mean age of 70.15 yrs. (SD = 7.54, range: 60-98). 110 (56.7%) were Medicare beneficiaries and 44 (22.68%) were privately insured. Nearly all visits (97.9%) were follow-up visits. 73.2% had inactive disease. Of the 144 with internal PCPs, 30% were vaccinated vs. 8% of 49 with external PCPs. 12.4% of patients had a documented history of herpes zoster. 72% of patients were on MTX (4 pts on ≥ 20 mg) and 54.64% on prednisone (2 pts on > 10 mg). 27 (13%) of patients were vaccinated with 11 vaccinations given within the institution. Total vaccination percentage was 13.9% with 92.6% of the vaccinations appropriately given. Vaccination was addressed by the rheumatologist in 7.7% of patients.

Conclusion:  Patients with internal vs. external PCPs were about 4 times more likely to be being vaccinated based on documentation. There was no difference in vaccination status based on insurance, disease duration, age of patients, or history of HZ. Similar to prior studies, rates of vaccination in eligible RA patients continue to be low even in large academic centers. Interventions to improve vaccination rates must be further explored with focus on collaboration between PCPs and rheumatologists.


Disclosure: A. Joglekar, None; A. Blaske, None; N. Annapureddy, None.

To cite this abstract in AMA style:

Joglekar A, Blaske A, Annapureddy N. Identifying Barriers to Zoster Vaccination Rates Among RA Patients in an Academic Rheumatology Practice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/identifying-barriers-to-zoster-vaccination-rates-among-ra-patients-in-an-academic-rheumatology-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-barriers-to-zoster-vaccination-rates-among-ra-patients-in-an-academic-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology